VF
IKT icon

Virtu Financial’s Inhibikase Therapeutics IKT Stock Holding History

Virtu Financial’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$41K Buy
24,607
+1,738
+8% +$3.09K ﹤0.01% 1314
2025
Q4 		$47K Buy
22,869
+9,423
+70% +$15K ﹤0.01% 1313
2025
Q3 		$22K Buy
+13,446
New +$23.3K ﹤0.01% 1268
2023
Q2 		– Sell
-2,245
Closed -$9K – 1739
2023
Q1 		$9K Buy
+2,245
New +$9.37K ﹤0.01% 1357

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Virtu Financial's IKT Position: Q1 2026 in Review

Virtu Financial increased its Inhibikase Therapeutics (IKT) stake by 7.6% in Q1 2026, buying an estimated $3.09K and bringing the position to 24,607 shares worth $41K. The position accounts for ﹤0.01% of the portfolio, ranked #1314.

Virtu Financial first reported a position in IKT in Q1 2023 and has held it in 4 quarters since. The position peaked at $47K in Q4 2025. 104 funds tracked by Wall St. Rank hold IKT as of Q1 2026.

  • Virtu Financial held 24,607 shares of Inhibikase Therapeutics worth $41K as of Q1 2026.
  • Virtu Financial bought 1,738 Inhibikase Therapeutics shares in Q1 2026, an estimated $3.09K.
  • Inhibikase Therapeutics made up ﹤0.01% of Virtu Financial's portfolio in Q1 2026, its #1314 holding.
  • Virtu Financial first reported a position in Inhibikase Therapeutics in Q1 2023 and has held it in 4 quarters since.
  • Virtu Financial's Inhibikase Therapeutics position peaked at $47K in Q4 2025.
  • 104 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q1 2026.

Based on Virtu Financial's 13F filing for Q1 2026, filed 14 May 2026.